Remove FDA Remove Presentation Remove World Health
article thumbnail

AI’s Ability to Manipulate Decision Making Requires a Moratorium on Its Use in Obtaining Consent for Biomedical Research

Bill of Health

Public Health Service’s (USPHS) Syphilis Study at Tuskegee , whose revelation to the public sparked today’s legal schema for regulating and protecting the research it funds (the “Common Rule”), as well as research done in anticipation of receiving FDA approval for marketing a new product. While the U.S.

article thumbnail

Psychedelic Inequities and Unexplored Risk: Colonization, Commercialization, and Regulation

Bill of Health

There is a common and problematic misconception that colonization was an isolated historical event and that the present is somehow divorced from its precedent. To explore how colonization drives health inequities, we have to acknowledge the causal relationship between what is past and what is present and think critically about colonization.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

SQA Regulatory Surveillance Summary for May and June 2024

SQA

This precautionary measure adopted by the agency aims to ensure the health and physical integrity of the Brazilian population since, to date, no studies have been presented to ANVISA that prove the effectiveness and safety of the phenol product for use in such procedures.

FDA 52
article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2023 – January

SQA

A new template for the Certificate of a Pharmaceutical Product will be put into use in line with China’s pharmaceutical export practices and the latest World Health Organization (WHO) guidelines. A concerted and collaborative effort is essential to address this threat to global health, economies, and security effectively.

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2022 – September/October

SQA

The EC presented a first draft for public comment to the revision of Annex 1 in 2017. The entry into force closes a long revision process, which has been driven jointly by PIC/S and the EMA GMP/GDP Inspectors Working Group (GMDP IWG) in close co-operation with the European Commission (EC) and the World Health Organization (WHO).

FDA 40
article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2023 – May And June

SQA

The main innovations presented in the new standard are: Increased scope of the standard, with the inclusion of anatomopathological and toxicology laboratories, among others. PCPC has long supported providing the FDA with the resources it needs to advance modern federal regulatory oversight of cosmetics and personal care products.

FDA 40
article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2023 – July and August 2023

SQA

The US FDA has already recognized the ability of 16 EU Member States to conduct GMP inspections of manufacturers of veterinary medicinal products. At the same time, the EU has recognized the US FDA as an equivalent authority to carry out these inspections. about how they use sunscreen products.

FDA 40